IL-12 ameliorates diabetic retinal neurodegeneration by activating phagocytosis of microglia via the TREM2/DAP12 pathway
Diabetic retinopathy (DR) is a prevalent neurovascular complication of diabetes that can lead to vision loss in its advanced stages. Identifying treatment targets to inhibit the progression of DR in its early stages is critical for preserving visual function. Interleukin-12 (IL-12) has emerged as a potential drug for treating early-stage diabetic retinal neurodegeneration.